Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs

Lisa E. Hines, Diana Ceron-Cabrera, Klaus Romero, Marietta Anthony, Raymond L. Woosley, Edward P Armstrong, Daniel C Malone

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information. Objective: The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin. Methods: We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia-Clinical Pharmacology, ePocrates®, and Micromedex®-and the warfarin US prescribing information (PI) as having an interaction with warfarin. The PI of each product was assessed for possible mention of an interaction with warfarin. The data were collected and tabulated by 1 investigator. A clinical investigator evaluated the data for accuracy and consistency. Unresolved issues were discussed with a third investigator and decided by consensus. The interaction listings were compared to determine similarities, differences, and inconsistencies and analyzed by 5 investigators. Results: Of the labeling for 73 products evaluated, 62 (85%) included mention of an interaction with warfarin. Those failing to mention the warfarin interaction were for older generic drugs or influenza vaccine. Among the labels listing an interaction with warfarin, the location of the information, the terminology used, and the inclusion of evidence for the interaction was inconsistent When considering the PI for all 73 products, Fleiss' kappa coefficient (κ = 0.467) suggested moderate concordance according to the method of Landis and Koch. Conclusion: This assessment of official US product labeling for 50 drugs, biologics, and drug classes known to interact with warfarin, comprising 73 distinct agents, found that 15% failed to mention the interaction, even though the interaction was mentioned in the warfarin labeling.

Original languageEnglish (US)
Pages (from-to)36-45
Number of pages10
JournalClinical Therapeutics
Volume33
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Warfarin
Drug Interactions
Pharmaceutical Preparations
Research Personnel
Product Labeling
Biological Products
Drug Labeling
Generic Drugs
Clinical Pharmacology
Influenza Vaccines
United States Food and Drug Administration
Terminology
Prescriptions

Keywords

  • Adverse drug event
  • Drug interaction
  • Food and Drug Administration
  • Product labeling
  • Warfarin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs. / Hines, Lisa E.; Ceron-Cabrera, Diana; Romero, Klaus; Anthony, Marietta; Woosley, Raymond L.; Armstrong, Edward P; Malone, Daniel C.

In: Clinical Therapeutics, Vol. 33, No. 1, 01.2011, p. 36-45.

Research output: Contribution to journalArticle

Hines, Lisa E. ; Ceron-Cabrera, Diana ; Romero, Klaus ; Anthony, Marietta ; Woosley, Raymond L. ; Armstrong, Edward P ; Malone, Daniel C. / Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs. In: Clinical Therapeutics. 2011 ; Vol. 33, No. 1. pp. 36-45.
@article{fcdcd1d91894473895dec25336c75fac,
title = "Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs",
abstract = "Background: Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information. Objective: The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin. Methods: We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia-Clinical Pharmacology, ePocrates{\circledR}, and Micromedex{\circledR}-and the warfarin US prescribing information (PI) as having an interaction with warfarin. The PI of each product was assessed for possible mention of an interaction with warfarin. The data were collected and tabulated by 1 investigator. A clinical investigator evaluated the data for accuracy and consistency. Unresolved issues were discussed with a third investigator and decided by consensus. The interaction listings were compared to determine similarities, differences, and inconsistencies and analyzed by 5 investigators. Results: Of the labeling for 73 products evaluated, 62 (85{\%}) included mention of an interaction with warfarin. Those failing to mention the warfarin interaction were for older generic drugs or influenza vaccine. Among the labels listing an interaction with warfarin, the location of the information, the terminology used, and the inclusion of evidence for the interaction was inconsistent When considering the PI for all 73 products, Fleiss' kappa coefficient (κ = 0.467) suggested moderate concordance according to the method of Landis and Koch. Conclusion: This assessment of official US product labeling for 50 drugs, biologics, and drug classes known to interact with warfarin, comprising 73 distinct agents, found that 15{\%} failed to mention the interaction, even though the interaction was mentioned in the warfarin labeling.",
keywords = "Adverse drug event, Drug interaction, Food and Drug Administration, Product labeling, Warfarin",
author = "Hines, {Lisa E.} and Diana Ceron-Cabrera and Klaus Romero and Marietta Anthony and Woosley, {Raymond L.} and Armstrong, {Edward P} and Malone, {Daniel C}",
year = "2011",
month = "1",
doi = "10.1016/j.clinthera.2011.01.021",
language = "English (US)",
volume = "33",
pages = "36--45",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs

AU - Hines, Lisa E.

AU - Ceron-Cabrera, Diana

AU - Romero, Klaus

AU - Anthony, Marietta

AU - Woosley, Raymond L.

AU - Armstrong, Edward P

AU - Malone, Daniel C

PY - 2011/1

Y1 - 2011/1

N2 - Background: Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information. Objective: The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin. Methods: We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia-Clinical Pharmacology, ePocrates®, and Micromedex®-and the warfarin US prescribing information (PI) as having an interaction with warfarin. The PI of each product was assessed for possible mention of an interaction with warfarin. The data were collected and tabulated by 1 investigator. A clinical investigator evaluated the data for accuracy and consistency. Unresolved issues were discussed with a third investigator and decided by consensus. The interaction listings were compared to determine similarities, differences, and inconsistencies and analyzed by 5 investigators. Results: Of the labeling for 73 products evaluated, 62 (85%) included mention of an interaction with warfarin. Those failing to mention the warfarin interaction were for older generic drugs or influenza vaccine. Among the labels listing an interaction with warfarin, the location of the information, the terminology used, and the inclusion of evidence for the interaction was inconsistent When considering the PI for all 73 products, Fleiss' kappa coefficient (κ = 0.467) suggested moderate concordance according to the method of Landis and Koch. Conclusion: This assessment of official US product labeling for 50 drugs, biologics, and drug classes known to interact with warfarin, comprising 73 distinct agents, found that 15% failed to mention the interaction, even though the interaction was mentioned in the warfarin labeling.

AB - Background: Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information. Objective: The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin. Methods: We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia-Clinical Pharmacology, ePocrates®, and Micromedex®-and the warfarin US prescribing information (PI) as having an interaction with warfarin. The PI of each product was assessed for possible mention of an interaction with warfarin. The data were collected and tabulated by 1 investigator. A clinical investigator evaluated the data for accuracy and consistency. Unresolved issues were discussed with a third investigator and decided by consensus. The interaction listings were compared to determine similarities, differences, and inconsistencies and analyzed by 5 investigators. Results: Of the labeling for 73 products evaluated, 62 (85%) included mention of an interaction with warfarin. Those failing to mention the warfarin interaction were for older generic drugs or influenza vaccine. Among the labels listing an interaction with warfarin, the location of the information, the terminology used, and the inclusion of evidence for the interaction was inconsistent When considering the PI for all 73 products, Fleiss' kappa coefficient (κ = 0.467) suggested moderate concordance according to the method of Landis and Koch. Conclusion: This assessment of official US product labeling for 50 drugs, biologics, and drug classes known to interact with warfarin, comprising 73 distinct agents, found that 15% failed to mention the interaction, even though the interaction was mentioned in the warfarin labeling.

KW - Adverse drug event

KW - Drug interaction

KW - Food and Drug Administration

KW - Product labeling

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=79952495577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952495577&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2011.01.021

DO - 10.1016/j.clinthera.2011.01.021

M3 - Article

VL - 33

SP - 36

EP - 45

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -